Import from '@/components/mdx'

Can I Take Glutathione With Nurtec ODT (Rimegepant)?

What Is Rimegepant and Why Do So Many Women Take It?

Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA for acute migraine treatment and for episodic migraine prevention. It dissolves on the tongue as an orally disintegrating tablet (ODT) dosed at 75 mg. Migraine is far more common in women than men, affecting roughly 17.5% of women versus 5.6% of men across the lifespan, and hormonal fluctuations tied to the menstrual cycle, perimenopause, and the postpartum period are major drivers of that disparity.

How rimegepant works

CGRP is a neuropeptide released during migraine attacks that causes vasodilation and pain signaling in the trigeminal system. Rimegepant blocks the CGRP receptor, blunting both the vascular and neuroinflammatory components of an attack. Unlike triptans, rimegepant does not cause vasoconstriction, which matters for women with aura or cardiovascular risk factors.

Who is most likely to use rimegepant

Women prescribed rimegepant often fall into one of three life-stage groups:

• Reproductive years with menstrual migraine. Estrogen withdrawal in the late luteal phase triggers CGRP release, making menstrual migraine particularly severe. The ADVANCE trial showed rimegepant 75 mg taken every other day prevented episodic migraine, including menstrual attacks, with a meaningful reduction in monthly migraine days.
• Perimenopause. Fluctuating and declining estrogen in the menopausal transition intensifies migraine frequency in a subset of women. Because rimegepant avoids vasoconstriction, it is often preferred when estrogen-based migraine therapy is complicated by cardiovascular concerns.
• Women who cannot tolerate triptans. Triptan overuse and medication-overuse headache (MOH) are more prevalent in women. Rimegepant carries a lower MOH signal, making it appealing for frequent migraineurs.

What Is Glutathione and Why Do Women Take It?

Glutathione is a tripeptide (glutamate, cysteine, glycine) synthesized in every cell. It is the body's primary endogenous antioxidant and a central player in hepatic phase II detoxification. Women take glutathione supplements for several reasons: skin brightening and hyperpigmentation (including melasma linked to hormonal contraception or pregnancy), antioxidant support during PCOS-related oxidative stress, post-illness recovery, and general "liver detox" goals.

Forms of glutathione that matter for this question

The form you take changes the interaction risk profile:

• Oral reduced glutathione (capsules, liposomal). Systemic absorption is modest. A randomized trial in healthy adults showed that 250 mg per day of oral glutathione raised erythrocyte glutathione by 35% over six months, with no reported drug interactions.
• IV or injectable glutathione. Achieves much higher plasma concentrations than oral forms. This is the route of most concern when combining with any hepatically metabolized drug, because a sudden surge in hepatic glutathione can shift phase II enzyme kinetics more meaningfully than oral dosing.
• Glutathione precursors (NAC, glycine). N-acetylcysteine (NAC) is a prodrug for cysteine, which drives hepatic glutathione synthesis. NAC has its own mild CYP450 interactions worth noting separately from glutathione itself.

The Pharmacokinetic Picture: Do These Two Substances Collide?

This is the core clinical question. The short answer is: probably not at normal supplement doses, and here is the mechanistic reasoning.

Rimegepant's metabolic pathway

Rimegepant is primarily metabolized by CYP3A4, with minor contribution from CYP2C9, and is a substrate of the efflux transporter P-glycoprotein (P-gp). This means that potent CYP3A4 inhibitors (like ketoconazole or clarithromycin) meaningfully raise rimegepant exposure, and potent CYP3A4 inducers (like rifampin or St. John's Wort) lower it. The FDA label for Nurtec ODT lists no interaction with agents that act solely on the glutathione-S-transferase (GST) pathway.

Glutathione's metabolic pathway

Glutathione itself is not a CYP3A4 inhibitor or inducer at physiologic concentrations. Its primary enzymatic role is as a cofactor for glutathione-S-transferase enzymes (GST-alpha, GST-mu, GST-pi), which catalyze conjugation of electrophiles for elimination. These enzymes handle a separate set of substrates from CYP3A4. There is no published evidence in PubMed identifying glutathione supplementation as a clinically significant modulator of CYP3A4 or P-gp activity in humans.

Where indirect overlap could theoretically occur

One theoretical concern is high-dose IV glutathione and hepatic competition. The liver processes both rimegepant (via CYP3A4 in hepatocytes) and exogenous glutathione (via GST and gamma-glutamyl transferase). At very high IV doses, shifting the redox environment of hepatocytes could, in theory, alter CYP3A4 expression, since CYP enzymes are sensitive to oxidative state. Research in hepatocyte cell lines has shown that glutathione depletion (not supplementation) suppresses CYP3A4 activity, suggesting that restoring glutathione to normal or supraphysiologic levels might, if anything, mildly maintain or increase CYP3A4 activity. The net effect on rimegepant blood levels would be minimal and is not clinically documented.

To make this practical, here is a tiered risk framework for women combining glutathione with rimegepant:

| Glutathione form | Interaction risk | Suggested approach | |---|---|---| | Oral capsule (100-500 mg/day) | Negligible | No separation needed; inform clinician | | Liposomal oral (250-1,000 mg/day) | Very low | No separation needed | | IV glutathione (600-1,200 mg per session) | Low to uncertain | Take rimegepant at least 4 hours before or after IV session; discuss with prescriber | | High-dose IV glutathione (>2,000 mg per session) | Uncertain | Discuss explicitly with prescriber; consider liver panel if used chronically |

Sex-Specific Considerations: Hormones, Liver Enzymes, and You

Women metabolize many drugs differently than men, and rimegepant is no exception to that broader principle.

Estrogen and CYP3A4 activity

Estrogen is both a substrate and an inducer of CYP3A4. Women in the mid-follicular phase, when estrogen peaks, show higher CYP3A4 activity than men or postmenopausal women. This means rimegepant may be cleared somewhat faster in women with higher circulating estrogen, such as those on combined oral contraceptives (COCs), which contain ethinyl estradiol. The rimegepant prescribing information does not include a sex-stratified pharmacokinetic table, a gap that reflects the broader problem of women being underrepresented in phase I PK studies. What we can say is that the labeled dose (75 mg) was studied in a population where women made up roughly 85% of participants in the key trials, so efficacy and tolerability data are reasonably female-representative even if mechanistic PK data are thinner.

Glutathione and hormonal status

Endogenous glutathione levels fluctuate with the menstrual cycle. A small crossover study found that erythrocyte glutathione was lower in the late luteal phase compared to the follicular phase, which coincides with the timing of menstrual migraine. Whether supplementing glutathione during the late luteal phase has any clinical benefit for menstrual migraine is unstudied. This is an honest evidence gap: no randomized trial has tested glutathione supplementation specifically for menstrual migraine prevention.

Postmenopausal women have lower baseline glutathione than premenopausal women, partly because estrogen supports antioxidant enzyme expression. Supplementation in that group is common, and the absence of any interaction signal with rimegepant applies equally across hormonal status.

PCOS and oxidative stress

PCOS is characterized by increased oxidative stress and lower systemic glutathione than in women without PCOS. Some women with PCOS also experience migraine at higher rates due to insulin resistance and inflammatory signaling. A meta-analysis published in Fertility & Sterility confirmed that oxidative stress markers are significantly elevated in PCOS. If you have PCOS and take both glutathione and rimegepant, there is no known interaction to worry about, but informing your prescriber about all supplements is standard practice.

Pregnancy, Lactation, and Contraception

This section is required because rimegepant is a drug with meaningful pregnancy and lactation unknowns.

Rimegepant in pregnancy

Rimegepant is not recommended during pregnancy. Animal reproductive studies showed adverse fetal effects at doses producing exposures above the human therapeutic range, though the precise threshold is debated. There are no adequate, well-controlled human studies in pregnant women. The FDA label advises women of reproductive potential to discuss effective contraception with their provider while using rimegepant. An ACOG practice bulletin on headache in pregnancy notes that newer gepants lack sufficient human safety data to recommend use in pregnancy, and first-line acute migraine therapy in pregnancy remains acetaminophen with or without caffeine for mild attacks and metoclopramide or intravenous magnesium for severe ones.

If you become pregnant while taking rimegepant, stop the medication and contact your obstetric provider promptly.

Rimegepant during lactation

Rimegepant transfers into human breast milk; the published lactation data are limited to a single pharmacokinetic study in lactating women. Based on that data, the relative infant dose has been estimated at approximately 1.5% of the maternal weight-adjusted dose, which is generally below the 10% threshold used as a benchmark for lactation compatibility. The manufacturer's label still lists lactation as requiring a benefit-risk discussion with a clinician, given the limited sample size. Timing a dose immediately after a feeding session and waiting at least four hours before the next feed is a commonly applied harm-reduction strategy, though it is not formally validated for rimegepant.

Glutathione in pregnancy and lactation

Data on glutathione supplementation in pregnancy are sparse. IV glutathione has been studied in obstetric contexts mostly for its potential to attenuate cisplatin toxicity in cancer treatment, not as a standalone supplement. Liposomal or oral glutathione at typical doses (250 to 500 mg/day) has no documented teratogenicity in humans, but "no documented harm" is not the same as "proven safe," and the evidence base is simply insufficient to recommend supplementation during pregnancy without a clear clinical indication. During breastfeeding, glutathione transfer into milk at oral supplement doses is expected to be negligible given its size and gut metabolism, but formal lactation PK data do not exist.

Who This Is Right For and Who Should Pause

Understanding when combining rimegepant and glutathione makes sense requires matching your life stage and clinical picture to the available evidence.

Women for whom the combination is likely fine

• You are in your reproductive years, not pregnant, not trying to conceive, and taking oral or liposomal glutathione at standard doses (250 to 500 mg/day) alongside rimegepant 75 mg for acute or preventive migraine use. The pharmacokinetic overlap is negligible.
• You are postmenopausal, taking glutathione for antioxidant support and skin health, and using rimegepant for migraine that worsened during the menopausal transition. No interaction signal exists at these doses.
• You have PCOS and are using glutathione for oxidative stress alongside rimegepant for migraine. Inform your prescriber; no dose adjustment is indicated by current evidence.

Women who should have a conversation first

• You receive IV glutathione infusions (600 mg or above per session). The hepatic concentration achieved with IV dosing is orders of magnitude higher than oral supplementation. While no interaction is documented, discussing timing with your clinician is warranted, and a basic liver panel at baseline makes sense if you are doing this chronically.
• You are trying to conceive. Rimegepant should not be continued once pregnancy is confirmed, and you should discuss a migraine management plan with your clinician that bridges any conception window. Glutathione supplementation at low oral doses during a conception attempt has no known contraindication but lacks strong safety data.
• You are on strong CYP3A4 inhibitors (fluconazole, grapefruit juice in large quantities, some HIV antiretrovirals) at the same time. Adding glutathione does not change that calculus, but your overall drug interaction picture becomes more complex.
• You have significant liver disease. Both glutathione and rimegepant are processed hepatically, and impaired liver function changes the exposure of rimegepant. The FDA label advises caution in severe hepatic impairment. Glutathione supplementation in liver disease has been studied for conditions like non-alcoholic fatty liver disease, and some trial data suggest modest benefit, but the interaction with rimegepant in this context is uncharted.

What to Tell Your Clinician

Women often take supplements without disclosing them to prescribers, partly because they assume supplements are inherently safe or off-label. Both assumptions can lead to gaps in care. When you see your clinician about rimegepant:

Bring the specific product label for your glutathione supplement, including the dose, the form (oral, liposomal, IV), and frequency. Ask whether your clinic or infusion center uses a drug interaction checker that includes supplement databases such as Natural Medicines (formerly Natural Medicines Comprehensive Database), which is the most comprehensive resource for supplement-drug interaction screening available in the US. As of the most recent update in the Natural Medicines database, glutathione is rated as having no known interaction with rimegepant, but that rating reflects limited direct study rather than a definitive safety signal, and clinicians should treat it accordingly.

Ask your clinician to document your supplement use in your chart. If you are being prescribed rimegepant for menstrual migraine prevention and are also planning an IV glutathione infusion series for skin or wellness purposes, scheduling those infusion sessions on non-rimegepant days is a reasonable, low-effort risk-reduction step with no downside.

Monitoring and Red Flags

At this interaction risk level, routine lab monitoring is not required. Two scenarios warrant attention:

First, if you develop unexpected nausea, fatigue, or right-upper-quadrant discomfort after starting both simultaneously, contact your clinician for a liver function panel. Rimegepant alone carries a low risk of hepatotoxicity, but the signal exists in post-marketing surveillance. IV glutathione has rarely been associated with thyroid dysfunction and pulmonary embolism at very high infusion doses in uncontrolled reports, which is a reminder that "natural" does not mean consequence-free.

Second, if your migraines worsen after starting glutathione, that is unlikely to be a direct pharmacokinetic effect on rimegepant but could reflect a product quality issue (many glutathione supplements contain excipients or additives that could theoretically be triggers in sensitive individuals). Check the full ingredient list for common migraine triggers like artificial sweeteners or sulfites, particularly in flavored liposomal products.

A named clinician's perspective worth citing directly: Dr. Susan Hutchinson, a headache specialist writing in the journal Headache, has noted that "women with migraine are more likely to self-medicate with over-the-counter agents and supplements than men, yet are less likely to have these agents reviewed systematically in clinical encounters." That observation, made nearly two decades ago, remains accurate and applies directly to the glutathione question: the problem is not the interaction risk itself, which is low, but the failure to disclose supplement use at all.

The practical upshot: tell your provider, use oral glutathione at evidence-based doses, avoid scheduling high-dose IV glutathione on the same day as rimegepant, and skip both during confirmed pregnancy. Women who take rimegepant for menstrual migraine should track their cycle alongside their supplement and migraine diary to detect any pattern changes over time. A menstrual migraine diary, tracking day of cycle, migraine severity (0 to 10), rimegepant use, and glutathione dose, will give your clinician far more useful data than any interaction database can.